Krensavage Asset Management LLC Reduces Stock Holdings in United Therapeutics Corporation $UTHR

Krensavage Asset Management LLC cut its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 17.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,282 shares of the biotechnology company’s stock after selling 15,000 shares during the quarter. United Therapeutics makes up about 14.3% of Krensavage Asset Management LLC’s holdings, making the stock its 3rd biggest holding. Krensavage Asset Management LLC’s holdings in United Therapeutics were worth $37,539,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. California State Teachers Retirement System increased its stake in shares of United Therapeutics by 55,526.2% during the second quarter. California State Teachers Retirement System now owns 33,288,952 shares of the biotechnology company’s stock valued at $18,036,953,000 after purchasing an additional 33,229,108 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of United Therapeutics in the 2nd quarter worth approximately $2,868,735,000. Wellington Management Group LLP increased its position in United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after buying an additional 1,042,711 shares in the last quarter. Jupiter Topco LLC bought a new position in United Therapeutics during the 2nd quarter valued at approximately $450,140,000. Finally, Norges Bank purchased a new position in United Therapeutics during the fourth quarter valued at $293,418,000. 94.08% of the stock is currently owned by institutional investors.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics entered a $477.6 million accelerated share repurchase agreement, representing the remainder of its previously authorized $2.0 billion buyback. The program should reduce shares outstanding and increase remaining shareholders’ ownership and per-share earnings. United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
• Positive Sentiment: Analyst sentiment remains favorable, with 11 Buy ratings and two Holds and a reported average price target of $646, well above the stock’s recent trading level. This supports the view that UTHR’s pulmonary arterial hypertension franchise and pipeline retain meaningful value.
• Neutral Sentiment: Management presented at the Cantor Fitzgerald Global Healthcare Conference and the Wells Fargo Healthcare Conference. The supplied reports do not identify a major new announcement, guidance change, or clinical update, so the presentations appear unlikely to create a significant near-term catalyst. Cantor Fitzgerald Global Healthcare Conference Transcript
• Negative Sentiment: CEO Martine Rothblatt disclosed sales of 9,500 UTHR shares for approximately $4.74 million at an average price of $499.03. A separate report describes another 9,500-share sale for about $4.65 million at $489.20. Each transaction reduced her direct ownership by 2.84%; while such sales may be personal or scheduled, repeated insider selling can weigh on sentiment. United Therapeutics Executive Share Sale
• Negative Sentiment: The latest quarterly results were mixed: earnings per share exceeded estimates, but revenue of $783.3 million missed expectations of $804.65 million and declined 1.9% year over year. The stock also remains below its 50-day and 200-day moving averages, indicating continued technical pressure.

Wall Street Analysts Forecast Growth

Several research firms have commented on UTHR. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. JPMorgan Chase & Co. upped their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Royal Bank Of Canada cut their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Finally, Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a research note on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $646.00.

Insiders Place Their Bets

In other news, EVP Paul Mahon sold 8,300 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $482.03, for a total transaction of $4,000,849.00. Following the transaction, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $21,774,259.16. This represents a 15.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $499.03, for a total value of $4,740,785.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $161,906,790.29. This trade represents a 2.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 384,075 shares of company stock valued at $202,738,638. Company insiders own 8.60% of the company’s stock.

United Therapeutics Stock Up 1.8%

Shares of UTHR stock opened at $506.82 on Thursday. The company has a 50 day moving average price of $523.12 and a 200-day moving average price of $540.39. United Therapeutics Corporation has a 52 week low of $395.00 and a 52 week high of $609.35. The firm has a market capitalization of $21.74 billion, a PE ratio of 18.13, a P/E/G ratio of 2.49 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter in the prior year, the firm earned $6.41 earnings per share. The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. Analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.